IL251729B - Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease - Google Patents
Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver diseaseInfo
- Publication number
- IL251729B IL251729B IL251729A IL25172917A IL251729B IL 251729 B IL251729 B IL 251729B IL 251729 A IL251729 A IL 251729A IL 25172917 A IL25172917 A IL 25172917A IL 251729 B IL251729 B IL 251729B
- Authority
- IL
- Israel
- Prior art keywords
- glucocorticoid
- receptor antagonists
- liver disease
- fatty liver
- disease treatment
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 208000010706 fatty liver disease Diseases 0.000 title 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251729A0 IL251729A0 (en) | 2017-06-29 |
| IL251729B true IL251729B (en) | 2020-03-31 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251729A IL251729B (en) | 2014-10-15 | 2017-04-13 | Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (enExample) |
| EP (3) | EP4792880A2 (enExample) |
| JP (1) | JP6761410B2 (enExample) |
| KR (1) | KR102435956B1 (enExample) |
| CN (2) | CN107106562B (enExample) |
| AU (1) | AU2015333645B2 (enExample) |
| BR (1) | BR112017007860B1 (enExample) |
| CA (1) | CA2964625C (enExample) |
| DK (2) | DK4353310T3 (enExample) |
| ES (1) | ES2978871T3 (enExample) |
| FI (2) | FI4353310T3 (enExample) |
| IL (1) | IL251729B (enExample) |
| MX (1) | MX2017004943A (enExample) |
| NZ (1) | NZ731060A (enExample) |
| PH (1) | PH12017500710B1 (enExample) |
| PL (1) | PL3206692T3 (enExample) |
| PT (2) | PT4353310T (enExample) |
| RU (1) | RU2718921C2 (enExample) |
| SG (1) | SG11201703024VA (enExample) |
| UA (1) | UA123537C2 (enExample) |
| WO (1) | WO2016061195A1 (enExample) |
| ZA (1) | ZA201702813B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| CA3102099C (en) * | 2018-06-04 | 2023-09-26 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| KR102911885B1 (ko) | 2020-05-06 | 2026-01-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체 |
| AU2021266739B2 (en) * | 2020-05-06 | 2024-11-28 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| JP7853982B2 (ja) * | 2020-12-21 | 2026-04-30 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法 |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| AU2022271209B2 (en) * | 2021-05-05 | 2026-07-02 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
| EP4732836A1 (en) | 2024-10-22 | 2026-04-29 | Consejo Superior De Investigaciones Científicas | Ag5 compound for use in the treatment of in fatty liver diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| EP1883624B1 (en) | 2005-05-18 | 2010-04-07 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| ES2546181T3 (es) | 2006-05-09 | 2015-09-21 | Genzyme Corporation | Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US20100144764A1 (en) * | 2007-04-13 | 2010-06-10 | Schering Corporation | Pyrimidinedione derivatives and methods of use thereof |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| CN103596431B (zh) * | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 FI FIEP24157529.9T patent/FI4353310T3/fi active
- 2015-10-14 PT PT241575299T patent/PT4353310T/pt unknown
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 DK DK24157529.9T patent/DK4353310T3/da active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 EP EP26180646.7A patent/EP4792880A2/en active Pending
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310B1/en active Active
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015333645B2 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| SG11201609645YA (en) | Device for connecting the structural elements of ribs and reticular structures | |
| IL247713A0 (en) | Indazole 3-carboxyamides converted at the 5-position, their preparation and their use | |
| AU201710083S (en) | Bowl and Covered Bowl | |
| SI3194564T1 (sl) | Sestavki trichoderme in postopki uporabe | |
| SG11201608217PA (en) | Fatty acid composition and use thereof | |
| IL246779A0 (en) | Methods for the treatment and prevention of kidney disorders and fatty liver disorders | |
| ZA201706671B (en) | Process for the preparation of androgen receptor antagonists and intermediates thereof | |
| IL246489A0 (en) | Methods for using anti-steap1 antibodies and immunoconjugates | |
| ZA201703398B (en) | Pharmaceutical composition and methods | |
| IL249203A0 (en) | Androgen receptor modulators and methods of using them | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| GB2530559B (en) | Mixing bowl | |
| IL265560A (en) | Preparations containing a mineralocorticoid receptor antagonist and their uses | |
| IL247828A0 (en) | Progesterone compounds | |
| IL246944B (en) | A process for the preparation of abiraterone acetate and its intermediates | |
| GB201612052D0 (en) | Animal claw shearing apparatuses and methods of using the same | |
| GB201520661D0 (en) | Mixing bowl | |
| GB201411741D0 (en) | Mixing bowl stand | |
| GB201402210D0 (en) | Mixing bowl | |
| GB201419977D0 (en) | Dynamic mixer and mixing | |
| GB201402629D0 (en) | Improved mixer and associated methods | |
| GB201419559D0 (en) | Therapeutic compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |